---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-090690"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2024-08-19T23:59:59+00:00"
generated_at: "2026-05-31T08:44:26.546177+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Apogee doses first healthy volunteers in Phase 1 trial of OX40L antibody APG990 for atopic dermatitis

## Summary
- Initiated dosing in Phase 1 trial of APG990, a half-life extended OX40L antibody, enrolling ~40 healthy volunteers in 5 cohorts.
- Interim safety and pharmacokinetic data from the Phase 1 trial expected in 2025.
- Plans to start combination trial of APG777 (IL-13) and APG990 in 2025 for broader efficacy in atopic dermatitis.
- CEO Michael Henderson: three programs advanced into clinical trials in 12 months since company's inception.

## SEC filing metadata
- accession: 0001104659-24-090690
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2024-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/0001104659-24-090690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000110465924090690/tm2421971d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-090690
- JSON: https://secwatch.observer/filing/0001104659-24-090690.json
- Plain text: https://secwatch.observer/filing/0001104659-24-090690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.